GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Equity-to-Asset

Bioasis Technologies (FRA:107) Equity-to-Asset : -1.53 (As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bioasis Technologies's Total Stockholders Equity for the quarter that ended in Nov. 2022 was €-1.97 Mil. Bioasis Technologies's Total Assets for the quarter that ended in Nov. 2022 was €1.29 Mil. Therefore, Bioasis Technologies's Equity to Asset Ratio for the quarter that ended in Nov. 2022 was -1.53.

The historical rank and industry rank for Bioasis Technologies's Equity-to-Asset or its related term are showing as below:

FRA:107's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Bioasis Technologies Equity-to-Asset Historical Data

The historical data trend for Bioasis Technologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Equity-to-Asset Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 -0.31 -2.64 0.12 -0.85

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.85 -1.67 -0.73 -1.53

Competitive Comparison of Bioasis Technologies's Equity-to-Asset

For the Biotechnology subindustry, Bioasis Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Equity-to-Asset falls into.



Bioasis Technologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bioasis Technologies's Equity to Asset Ratio for the fiscal year that ended in Feb. 2022 is calculated as

Equity to Asset (A: Feb. 2022 )=Total Stockholders Equity/Total Assets
=-1.329/1.571
=-0.85

Bioasis Technologies's Equity to Asset Ratio for the quarter that ended in Nov. 2022 is calculated as

Equity to Asset (Q: Nov. 2022 )=Total Stockholders Equity/Total Assets
=-1.966/1.285
=-1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioasis Technologies  (FRA:107) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Bioasis Technologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies Headlines

No Headlines